Predictors of Response to Targeted Therapy in Renal Cell Carcinoma
作者： Laurie J. Eisengart , Gary R. MacVicar , Ximing J. Yang
DOI: 10.5858/ARPA.2010-0308-RA
关键词:
摘要: Context.—The prognosis for patients with metastatic renal cell carcinoma is poor, an average 5-year survival of approximately 10%. Use traditional cytokine therapy, specifically high-dose interleukin 2, limited by significant toxicity. Better understanding the molecular pathogenesis has led to development targeted therapies inhibit specific cellular pathways leading tumorigenesis. These drugs provide improved a more favorable toxicity profile. There ongoing investigation markers that predict response individual patient different therapies. Objective.—To explain basis vascular endothelial growth factor inhibitor (antiangiogenic) and mammalian target rapamycin carcinoma, summarize clinical trials demonstrating effectiveness these drugs, describe biomarkers shown correlate outcome in treated therapy. Data Sources.—Al...
allenpress.com
archivesofpathology.org参考文章(58)
Peter J Houghton, Shile Huang, Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Current opinion in investigational drugs. ,vol. 3, pp. 295- 304 ,(2002)
Teh Bt, Yang Xj, Adley Bp, Sugimura J, Papavero, Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Analytical and Quantitative Cytology and Histology. ,vol. 28, pp. 228- 236 ,(2006)
Andrew N. Young, Mahul B. Amin, Carlos S. Moreno, So Dug Lim, Cynthia Cohen, John A. Petros, Fray F. Marshall, Andrew S. Neish, Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. American Journal of Pathology. ,vol. 158, pp. 1639- 1651 ,(2001) , 10.1016/S0002-9440(10)64120-X
Berton Zbar, Hitoshi Kitamura, Takeshi Kishida, Farida Latif, Masahiko Hosaka, Michael I. Lerman, Kelichi Kondo, Yoshinobu Kubota, Masahiro Yao, Soichiro Torigoe, Yoji Nagashima, Taro Shuin, Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Research. ,vol. 54, pp. 2852- 2855 ,(1994)
Toni K. Choueiri, Meredith M. Regan, Jonathan E. Rosenberg, William K. Oh, Jessica Clement, Angela M. Amato, David McDermott, Daniel C. Cho, Michael B. Atkins, Sabina Signoretti, Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJUI. ,vol. 106, pp. 772- 778 ,(2010) , 10.1111/J.1464-410X.2010.09218.X
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Arie S. Belldegrun, Tobias Klatte, Brian Shuch, Jeffrey C. LaRochelle, David C. Miller, Jonathan W. Said, Stephen B. Riggs, Nazy Zomorodian, Fairooz F. Kabbinavar, Jean B. deKernion, Allan J. Pantuck, Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005) Cancer. ,vol. 113, pp. 2457- 2463 ,(2008) , 10.1002/CNCR.23851
Edward M. Schaeffer, Thomas J. Guzzo, Kyle A. Furge, George Netto, Michael Westphal, Karl Dykema, Ximing Yang, Ming Zhou, Bin Tean Teh, Christian P. Pavlovich, Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase‐inhibiting therapy BJUI. ,vol. 106, pp. 62- 65 ,(2009) , 10.1111/J.1464-410X.2009.09139.X
Audrey N. Schuetz, Qiqin Yin-Goen, Mahul B. Amin, Carlos S. Moreno, Cynthia Cohen, Christopher D. Hornsby, Wen Li Yang, John A. Petros, Muta M. Issa, John G. Pattaras, Kenneth Ogan, Fray F. Marshall, Andrew N. Young, Molecular Classification of Renal Tumors by Gene Expression Profiling The Journal of Molecular Diagnostics. ,vol. 7, pp. 206- 218 ,(2005) , 10.1016/S1525-1578(10)60547-8
Ellen C. Breen, VEGF in biological control Journal of Cellular Biochemistry. ,vol. 102, pp. 1358- 1367 ,(2007) , 10.1002/JCB.21579